• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Breast cancer and the pill--a further report from the Royal College of General Practitioners' oral contraception study.乳腺癌与避孕药——皇家全科医师学院口服避孕药研究的进一步报告
Br J Cancer. 1988 Nov;58(5):675-80. doi: 10.1038/bjc.1988.285.
2
The Royal College of General Practitioners' Oral Contraception Study: some recent observations.皇家全科医师学院口服避孕药研究:近期一些观察结果。
Clin Obstet Gynaecol. 1984 Dec;11(3):759-86.
3
Weighing the evidence on the pill and breast cancer.权衡关于避孕药与乳腺癌的证据。
Fam Plann Perspect. 1989 Mar-Apr;21(2):89-92.
4
The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study.口服避孕药使用者患重病的风险:来自皇家全科医师学院口服避孕药研究的证据。
Br J Gen Pract. 1998 Oct;48(435):1657-62.
5
Oral contraceptives and breast cancer.口服避孕药与乳腺癌
Int J Epidemiol. 1982 Dec;11(4):316-22. doi: 10.1093/ije/11.4.316.
6
Mortality among oral contraceptive users: 20 year follow up of women in a cohort study.口服避孕药使用者的死亡率:队列研究中女性的20年随访
BMJ. 1989 Dec 16;299(6714):1487-91. doi: 10.1136/bmj.299.6714.1487.
7
Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?性甾体激素与乳腺癌:与口服避孕药及激素替代疗法有关联吗?
Med J Aust. 1992 Jan 20;156(2):124-32.
8
Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.终生癌症风险与口服避孕药:皇家全科医生学院口服避孕药研究。
Am J Obstet Gynecol. 2017 Jun;216(6):580.e1-580.e9. doi: 10.1016/j.ajog.2017.02.002. Epub 2017 Feb 8.
9
Oral contraceptives and risk of breast cancer in women aged 20-54 years. Netherlands Oral Contraceptives and Breast Cancer Study Group.口服避孕药与20 - 54岁女性患乳腺癌的风险。荷兰口服避孕药与乳腺癌研究小组。
Lancet. 1994 Sep 24;344(8926):844-51. doi: 10.1016/s0140-6736(94)92826-6.
10
Oral contraceptives as related to cancer and benign lesions of the breast.口服避孕药与乳腺癌及乳腺良性病变的关系
J Natl Cancer Inst. 1975 Oct;55(4):767-73. doi: 10.1093/jnci/55.4.767.

引用本文的文献

1
[Hormonal contraception and breast cancer risk].[激素避孕与乳腺癌风险]
Wien Med Wochenschr. 2010 Nov;160(19-20):483-6. doi: 10.1007/s10354-010-0807-0. Epub 2010 Aug 16.
2
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease.酒精、烟草与乳腺癌——对53项流行病学研究的个体数据进行的联合重新分析,其中包括58515名乳腺癌女性患者和95067名未患该病的女性。
Br J Cancer. 2002 Nov 18;87(11):1234-45. doi: 10.1038/sj.bjc.6600596.
3
Oral contraceptive use at a young age and the risk of breast cancer: an Icelandic, population-based cohort study of the effect of birth year.年轻时使用口服避孕药与乳腺癌风险:一项基于冰岛人群的出生年份效应队列研究。
Br J Cancer. 1997;75(1):139-43. doi: 10.1038/bjc.1997.23.
4
Recent oral contraceptive use and risk of breast cancer (United States).近期口服避孕药的使用与乳腺癌风险(美国)
Cancer Causes Control. 1996 Sep;7(5):525-32. doi: 10.1007/BF00051885.
5
Oral contraceptives and cancer. A review of the evidence.口服避孕药与癌症。证据综述。
Drug Saf. 1996 Apr;14(4):260-72. doi: 10.2165/00002018-199614040-00006.
6
Epidemiology of in situ and invasive breast cancer in women aged under 45.45岁以下女性原位和浸润性乳腺癌的流行病学
Br J Cancer. 1996 May;73(10):1298-305. doi: 10.1038/bjc.1996.248.
7
Exogenous hormone use and the risk of postmenopausal breast cancer: results from The Netherlands Cohort Study.外源性激素使用与绝经后乳腺癌风险:荷兰队列研究结果
Cancer Causes Control. 1995 Sep;6(5):416-24. doi: 10.1007/BF00052181.
8
Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.炔诺孕酮和孕二烯酮通过雌激素受体介导的机制刺激乳腺癌细胞生长。
Br J Cancer. 1993 May;67(5):945-52. doi: 10.1038/bjc.1993.175.
9
Breast cancer screening for women younger than 40.40岁以下女性的乳腺癌筛查。
Can Fam Physician. 1993 Jan;39:65-72.
10
Oral contraceptives and breast cancer in northern Italy. Final report from a case-control study.意大利北部的口服避孕药与乳腺癌。一项病例对照研究的最终报告。
Br J Cancer. 1993 Sep;68(3):568-71. doi: 10.1038/bjc.1993.387.

本文引用的文献

1
Oral contraceptive use and early abortion as risk factors for breast cancer in young women.口服避孕药的使用和早期流产作为年轻女性患乳腺癌的风险因素。
Br J Cancer. 1981 Jan;43(1):72-6. doi: 10.1038/bjc.1981.10.
2
Breast cancer in relation to patterns of oral contraceptive use.与口服避孕药使用模式相关的乳腺癌
Am J Epidemiol. 1982 Oct;116(4):643-51. doi: 10.1093/oxfordjournals.aje.a113447.
3
Breast cancer and oral contraceptive use.乳腺癌与口服避孕药的使用。
Am J Epidemiol. 1984 Feb;119(2):167-76. doi: 10.1093/oxfordjournals.aje.a113735.
4
Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use.年轻女性乳腺癌与口服避孕药的使用:制剂类型及开始使用年龄可能的调节作用
Lancet. 1983 Oct 22;2(8356):926-30. doi: 10.1016/s0140-6736(83)90450-6.
5
Age at first birth and breast cancer risk.初产年龄与乳腺癌风险。
Bull World Health Organ. 1970;43(2):209-21.
6
Breast cancer risk in relation to early oral contraceptive use.
Obstet Gynecol. 1986 Dec;68(6):863-8.
7
Early oral contraceptive use and breast cancer: results of another case-control study.早期口服避孕药的使用与乳腺癌:另一项病例对照研究的结果
Br J Cancer. 1987 Nov;56(5):653-60. doi: 10.1038/bjc.1987.261.
8
Oral contraceptives and breast cancer: a national study.口服避孕药与乳腺癌:一项全国性研究。
Br Med J (Clin Res Ed). 1986 Sep 20;293(6549):723-6. doi: 10.1136/bmj.293.6549.723.
9
Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway.年轻女性口服避孕药与乳腺癌。瑞典和挪威的一项联合全国病例对照研究。
Lancet. 1986 Sep 20;2(8508):650-4. doi: 10.1016/s0140-6736(86)90166-2.
10
Oral contraceptive use and breast cancer in young women in Sweden.瑞典年轻女性口服避孕药与乳腺癌的关系
Lancet. 1985 Mar 30;1(8431):748-9. doi: 10.1016/s0140-6736(85)91280-2.

乳腺癌与避孕药——皇家全科医师学院口服避孕药研究的进一步报告

Breast cancer and the pill--a further report from the Royal College of General Practitioners' oral contraception study.

作者信息

Kay C R, Hannaford P C

机构信息

RCGP Manchester Research Unit, UK.

出版信息

Br J Cancer. 1988 Nov;58(5):675-80. doi: 10.1038/bjc.1988.285.

DOI:10.1038/bjc.1988.285
PMID:3219280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2246833/
Abstract

An analysis of the occurrence of breast cancer in this long-term prospective cohort study shows a significant relative risk (RR) in women who have ever used oral contraceptives (OC) of 3.33 in women age 30 to 34 years at diagnosis and an RR of 5.88 (P = 0.0011) in women who were parity 1 at the time of diagnosis. In women below the age of 35 years the RR of 2.38 was not significant. There was no increased risk in women over the age of 35 years. A significant trend relating to duration of use was demonstrable in women who were parity 1 in the analysis of both current and ever-users. An analysis by time since stopping OC use revealed a significant trend in all ever-users, but the trends were much steeper in women of parity 1 or aged 30 to 34 years at diagnosis. There was no evidence that the increased rates in OC users were related to the oestrogen or progestogen dose. The 5 year survival rate in users diagnosed under the age of 35 years was significantly poorer than in comparable non-users. It is possible that the increased rates in younger OC users might be due to an accelerated presentation of breast cancer in those women who would otherwise have been diagnosed at a later time. The non-significant excess risk in users under 35 years of age was approximately 1 in 7,000 users per year. The unresolved discrepancies between the results of the published studies make it impossible at the present time to decide whether or not OC use is associated with an increased risk of breast cancer.

摘要

在这项长期前瞻性队列研究中,对乳腺癌发病情况的分析显示,诊断时年龄在30至34岁且曾使用口服避孕药(OC)的女性,其相对风险(RR)显著为3.33;诊断时为初产妇的女性,RR为5.88(P = 0.0011)。35岁以下女性的RR为2.38,不具有显著性。35岁以上女性没有增加的风险。在对现使用者和曾使用者的分析中,对于初产妇,使用时间与风险之间存在显著趋势。按停止使用OC后的时间进行分析显示,所有曾使用者都有显著趋势,但在诊断时为初产妇或年龄在30至34岁的女性中,趋势更为明显。没有证据表明OC使用者中发病率的增加与雌激素或孕激素剂量有关。35岁以下被诊断出的使用者的5年生存率显著低于可比的未使用者。年轻OC使用者发病率增加可能是由于那些原本会在更晚时候被诊断出乳腺癌的女性中,乳腺癌的发病加速。35岁以下使用者中不显著的额外风险约为每年每7000名使用者中有1例。已发表研究结果之间未解决的差异使得目前无法确定使用OC是否与乳腺癌风险增加有关。